Nanocurcumin 80 mg three times daily,
does it really help with Improvement of HOMA-IR in polycystic ovary syndrome?
research showsGrade C with 54 points. A 200-participant 2×2 factorial trial emphasized metabolic improvements with metformin plus nanocurcumin, but the public abstract does not isolate the nanocurcumin main effect or interaction with an exact HOMA-IR contrast and 95% CI.
ads claimThe combination arm cannot justify claims that nanocurcumin alone corrects insulin resistance, weight, and hormones.
Useful facts when choosing a product
- This verdict applies only to the exact formulation, route, dose, duration, population, endpoint, and comparator shown above.
- Conventional curcumin, turmeric powder, nano or micellar products, phospholipid phytosomes, piperine combinations, swallowed products, and topical oral products are not interchangeable.
- Caution. Nanocurcumin safety in pregnancy is not established; gastrointestinal and glycemic effects require clinical monitoring when combined with metformin.
Chamgap Semantic Classification Code
Permanent code issued
S.nanocurcumin.oral.homa-ir.improve.factorialSupplements and nutraceuticals > Nanocurcumin > Oral > HOMA-IR > Improvement claim > Metformin 2x2 factorial comparison
Bound to the PCOS 2x2 factorial trial; combination-arm results are not attributed to nanocurcumin alone. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Nanocurcumin |
| Source or part used | Nanoformulated curcumin derived from Curcuma longa |
| Formulation or processing | Nanocurcumin soft-gel capsule |
| Route | Oral |
| Dose | 80 mg every 8 hours, 240 mg/day |
| Duration | 12 weeks of treatment and follow-up |
| Population | 200 women with PCOS; diagnostic details governed by the full paper |
| Effect or condition | HOMA-IR improvement |
| Primary endpoint | Change in HOMA-IR at 12 weeks |
| Comparator | Double placebo and metformin factorial arms |
| Duplicate-detection key | nanocurcumin|softgel|oral|women-pcos|homa-ir-improvement|12-weeks |
What the research actually shows
A 2×2 factorial trial switching metformin and nanocurcumin on and off independently was reviewed.
Why this is classified as C (54)
Sample size and duration are strengths, but unverified isolated main effect, hierarchy, and confidence interval impose an EX cap, yielding C with 54 points.
Counterpoint. The 200-person, 12-week double-blind placebo-controlled design is a strength, but the exact isolated HOMA-IR estimate is absent from the public abstract.
Rejudgment record. Independent Codex cross-check — One formulation, one route, one population, one claim, one principal endpoint and comparator
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Effects of metformin and curcumin in women with polycystic ovary syndrome: A factorial clinical trial | The cited design and its allocation, masking, endpoint, and analysis limitations were independently checked. | 1 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint is preserved; secondary and mechanistic outcomes remain separate. | The verified numerical result is preserved in the English reader answer and rationale; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and verified analysis limitations. |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-09-08).
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Nanocurcumin for PCOS HOMA-IR—A 200-Participant Factorial Trial Did Not Cleanly Isolate the Combination Signal — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/oral-nanocurcumin-pcos-homa-ir-factorial/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.